Wednesday, October 27, 2021 Daily Archives

BioNTech eyes mid-2022 to build mRNA facility in Africa

BioNTech has struck a deal with Rwanda and Senegal to begin building a mRNA vaccine production plant in Africa next year. The decision to start building a messenger RNA (mRNA) plant next summer comes after the German biotech signed a memorandum of understanding (MoU) with the Rwandan government and Institut Pasteur de Dakar in Senegal this week. The firm had previously expressed the possibility of setting up mRNA manufacturing facilities on its own, or with partners in Africa and according…

EnteroBiotix completes Scottish microbial facility

The mechanically complete facility in Strathclyde, Scotland will establish EnteroBiotix’s pipeline and provide end-to-end control of the supply chain, says firm. EnteroBiotix is a biopharmaceutical company focused on developing microbial therapeutics, which aim to treat debilitating diseases and infections associated with the function and structure of the gut microbiome. The mechanical completion of its purpose-built manufacturing donor-derived microbial therapeutic plant at Strathclyde Business Park, Scotland spans over 20,000 square feet and includes expansion of its corporate offices to support an…

Quality gene therapies require quality analytics

Gene therapy quality depends on choosing the right analytical methods and technologies for each part of the production process says an expert from Biomarin. Lyndi Rice, head of the QC viral vector analytical group at Biomarin Pharmaceutical, told delegates at the BPI East conference in September: “Analytics are really critical from the start of the manufacturing process and all the way to the end of product testing and monitoring. “Release testing is critical for measuring product quality by assessing its…